Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
Angiogenesis inhibitor. Additionally we are shipping Vasohibin 1 Antibodies (68) and Vasohibin 1 Proteins (5) and many more products for this protein.
Showing 4 out of 5 products:
Studied angiogenic activity of vasohibin-1 (VASH1), by analyzing levels of VASH1 in both RCC (show XRCC1 ELISA Kits) tissue and non-neoplastic kidney tissue. Found elevated VASH1 density, but not microvascular density, was a significant and independent predictor of overall survival in RCC (show XRCC1 ELISA Kits).
identified a novel UPS regulatory system in which essential domain architecture (VASH-PS) of VASHs, comprising regions VASH191-180 and VASH280-169 , regulate the cytosolic punctate structure formation in the absence of SVBP.
replicative senescence, the downregulation of VASH1 expression in endothelial cells was caused, at least in part, by the alteration of microRNA expression.
VASH1 expression is associated with tumour progression and may be useful as a prognostic marker of head and neck squamous cell carcinoma
VASH1 expression inhibited tumor vascularization and growth, not only in high VEGF (show VEGFA ELISA Kits)-producing cells, but also in high PDGF (show PDGFA ELISA Kits)-producing cells, reduced their peritoneal dissemination and ascites, and prolonged the survival time of the host
in this study, the length of tube forming structures of endothelial cells in vitro showed that Vasohibin-1 expression in gastric cancer cells significantly decreased the ability of vessel formation of endothelium cells.
These results indicate that cancer cells proteolytically inactivate VASH1 protein secreted by ECs in the tumour microenvironment
VASH1 exerts an antitumor effect on ovarian cancer by inhibiting angiogenesis in the tumor environment
VASH1 expression levels in atheroma reflects both enhanced neovascularization and the inflammatory burden
Knockdown of VASH1 in cancer cells promoted cell growth, adhesion and migration in vitro, and enhanced tumorigenesis and metastasis in vivo.
Unaffected fibrosis and angiogenesis seen by knocking out endogenous vasohibin-1.
endogenous VASH1 may regulate the development of diabetic renal alterations
VASH1 and VASH2 showed distinctive localization and opposing function on the fetoplacental vascularization.
PKCdelta (show PKCd ELISA Kits) deficiency enhances neointimal formation, which is associated with delayed reendothelialization and involves increased cellular vasohibin-1 accumulation.
vasohibin1 is the first known intrinsic factor (show GIF ELISA Kits) having broad-spectrum antilymphangiogenic activity
These results suggest a role for VASH1 in negative feedback regulation of haematopoietic progenitors proliferation during recovery following bone marrow ablation.
Loss of vasohibin-1 is associated with persistent angiogenesis in the termination zone of endothelial cells.
These results suggest that endogenous vasohibin-1 is involved in tumor angiogenesis and exogenous vasohibin-1 blocks sprouting angiogenesis by tumors, matures the remaining vessels, and enhances the antitumor effect of conventional chemotherapy
results demonstrate expression of VASH1, especially in blood vascular endothelial cells in the corpus luteum (CL) and show VASH1 inhibits VEGFA (show VEGFA ELISA Kits)-stimulated capillary like-tube formation by luteal endothelial cells and lymphatic endothelial cells vitro; results indicate VASH1 may act as a negative feedback regulator of angiogenesis and lymphangiogenesis in the CL
Angiogenesis inhibitor. Inhibits migration, proliferation and network formation by endothelial cells as well as angiogenesis. This inhibitory effect is selective to endothelial cells as it does not affect the migration of smooth muscle cells or fibroblasts. Does not affect the proliferation of cancer cells in vitro, but inhibits tumor growth and tumor angiogenesis. Acts in an autocrine manner. Inhibits artery neointimal formation and macrophage infiltration. Exhibits heparin-binding activity.